浩欧博(688656) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 76.09 million, representing a year-on-year increase of 24.75%[5] - The net profit attributable to shareholders was CNY 13.56 million, with a slight increase of 1.69% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses increased by 17.07% year-on-year, amounting to CNY 12.99 million[7] - The basic earnings per share for the period was CNY 0.22, a decrease of 4.35% compared to the previous year[6] - The total operating profit for Q1 2022 was CNY 16,371,087.78, compared to CNY 14,534,958.39 in Q1 2021, indicating an increase of about 12.7%[21] - The net profit for Q1 2022 was CNY 13,562,324.81, a slight increase from CNY 13,336,533.53 in Q1 2021, representing a growth of approximately 1.7%[21] - The total revenue from sales of goods and services received in Q1 2022 was CNY 86,163,503.68, an increase from CNY 70,738,820.18 in Q1 2021, representing a growth of approximately 21.8%[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 875.01 million, an increase of 1.28% from the end of the previous year[6] - As of March 31, 2022, the company's total current assets amounted to approximately CNY 520.64 million, a decrease from CNY 569.97 million at the end of 2021, representing a decline of about 8.6%[17] - Cash and cash equivalents decreased to CNY 138.93 million from CNY 449.86 million, indicating a significant reduction of approximately 69.0% year-over-year[17] - The company’s trading financial assets increased to CNY 263.71 million from CNY 5.01 million, showing a substantial growth of approximately 5171.5%[17] - Accounts receivable decreased to CNY 31.23 million from CNY 37.48 million, reflecting a decline of about 16.7%[17] - Inventory increased slightly to CNY 70.33 million from CNY 68.20 million, marking a growth of approximately 3.1%[17] - Non-current assets totaled ¥354,369,881.62 as of March 31, 2022, up from ¥293,947,952.55 at the end of 2021, indicating a growth of 20.5%[19] - Current liabilities increased to ¥76,864,482.98 from ¥86,166,555.85, showing a decrease of 10.5%[19] - The company's equity attributable to shareholders reached ¥786,105,802.45, up from ¥770,001,650.91 at the end of 2021, reflecting a growth of 2.1%[19] Cash Flow - The net cash flow from operating activities was CNY 4.04 million, down 45.76% due to increased material purchases and employee compensation[10] - Cash flow from operating activities for Q1 2022 was CNY 4,038,411.21, down from CNY 7,445,872.43 in Q1 2021, reflecting a decrease of approximately 45.5%[24] - The total cash inflow from investment activities in Q1 2022 was CNY 30,194,986.30, while cash outflow was CNY 353,438,688.26, resulting in a net cash flow of -CNY 323,243,701.96[24] - The cash and cash equivalents at the end of Q1 2022 stood at CNY 138,929,515.77, a significant decrease from CNY 506,416,822.95 at the end of Q1 2021[25] - The total operating cash outflow for Q1 2022 was CNY 85,597,750.10, compared to CNY 65,537,101.84 in Q1 2021, indicating an increase of about 30.6%[24] - The company recorded a cash flow from financing activities of CNY 8,463,334.83 in Q1 2022, a decrease from CNY 479,469,346.49 in Q1 2021[24] Research and Development - Research and development expenses totaled CNY 7.21 million, accounting for 9.48% of operating revenue, a decrease of 1.19 percentage points year-on-year[6] - Research and development expenses increased to ¥7,213,239.18, compared to ¥6,508,135.29 in the same period last year, reflecting a growth of 10.8%[20] - Future outlook includes continued investment in R&D for new products and technologies to maintain competitive advantage in the market[15] Strategic Initiatives - The company is focusing on enhancing its brand influence and improving its marketing service network as part of its long-term strategic development[15] - The establishment of new subsidiaries and increased investment in technology are part of the company's strategy to strengthen its product lines in allergy and autoimmune sectors[15] - The company reported a net profit growth slowdown in Q1 2022 due to increased investments in new product development and expansion of production facilities[15] - The company has not disclosed any significant mergers or acquisitions during the reporting period[15] Shareholder Information - The top shareholder, Hai Rui Xiang Tian Biological Technology, holds 3.51 million shares, accounting for 55.66% of total shares[12] - The total number of ordinary shareholders at the end of the reporting period was 3,753[12] Tax and Expenses - The company reported a tax expense of CNY 2,918,406.39 for Q1 2022, significantly higher than CNY 1,262,762.88 in Q1 2021, reflecting an increase of approximately 131.9%[21] - Total operating costs for Q1 2022 were ¥60,549,001.54, up 23.5% from ¥49,022,520.49 in Q1 2021[20] - Gross profit for Q1 2022 was ¥15,538,324.41, representing a gross margin of 20.4%[20] - The company reported a net investment income of ¥171,807.06, a significant decrease from ¥2,567,085.16 in Q1 2021[20]